News & Updates
Filter by Specialty:
Baricitinib keeps radiographic progression levels low in rheumatoid arthritis
Treatment with oral baricitinib steadily inhibits radiographic progression of structural joint damage in most patients with rheumatoid arthritis (RA), while achieving clinical improvement in disease activity, through 5 years as compared with initial conventional synthetic disease-modifying antirheumatic drug (csDMARD) or placebo, results of a study have shown.
Baricitinib keeps radiographic progression levels low in rheumatoid arthritis
24 Feb 2022
Are patients with psoriatic arthritis at higher risk of death?
Patients with psoriatic arthritis (PsA) do not appear to be at increased risk of mortality from all causes, reveals a study. Moreover, the specific proportionate mortality rate (PMR) in this cohort is similar to that of the general population.
Are patients with psoriatic arthritis at higher risk of death?
23 Feb 2022
First-line biologic therapy persists longer than later agents in ankylosing spondylitis
Biologic disease-modifying antirheumatic drug (bDMARD) therapy is effective in reducing ankylosing spondylitis (AS) disease activity, reports a study, noting how treatment has persisted for up to 8 years among patients remaining on their first bDMARD, which is longer than on subsequent agents.
First-line biologic therapy persists longer than later agents in ankylosing spondylitis
22 Feb 2022
Lower SLERPI cutoff improves early diagnosis in SLE patients with fever, thrombosis
Hospitalization is warranted in one in five patients with new-onset systemic lupus erythematosus (SLE) manifest disease presentations, according to a recent study. Of note, diagnosis has been delayed in nearly 20 percent of patients.
Lower SLERPI cutoff improves early diagnosis in SLE patients with fever, thrombosis
19 Feb 2022
KEEPsAKE findings boost risankizumab efficacy, safety for PsA
In individuals with psoriatic arthritis (PsA) who have inadequate response or intolerance to ≥1 csDMARD*, the monoclonal antibody risankizumab significantly improved manifestations of PsA, according to the 24-week findings of the phase III KEEPsAKE 1 trial.
KEEPsAKE findings boost risankizumab efficacy, safety for PsA
24 Jan 2022
Osteoporosis drug holidays tied to small rise in hip fracture risk
The risk for hip fracture slightly increases following osteoporosis drug holidays after long-term therapy with risedronate compared with alendronate, a study has found, adding that future research must examine how best to lessen such risk.
Osteoporosis drug holidays tied to small rise in hip fracture risk
21 Jan 2022
Are pregnant women with rheumatic disease at risk of poor COVID-19 outcomes?
Pregnant women with rheumatic disease and COVID-19 show favourable outcomes, but data are limited by the small sample size and methodology, reports a study.
